[3"-Chloro-2-fluoro-5'-(8-phenyl-octylcarbamoyl)-[1,1';3',1"]terphenyl-2'-yloxy]-acetic acid

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: [3"-Chloro-2-fluoro-5'-(8-phenyl-octylcarbamoyl)-[1,1';3',1"]terphenyl-2'-yloxy]-acetic acid
• 英文别名: 2-[2-(3-Chlorophenyl)-6-(2-fluorophenyl)-4-(8-phenyloctylcarbamoyl)phenoxy]acetic acid
• 化学式: C₃₅H₃₅ClFNO₄
• 分子量: 588.119
• InChiKey: XXWLJNIQIXRDOR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  9.6
• 重原子数：
  42
• 可旋转键数：
  15
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.26
• 拓扑面积：
  75.6
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  过氧化氢酶 在 (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride N-溴代丁二酰亚胺(NBS) 、 tetrafluoroboric acid 、 正丁基锂 、 四丙基高钌酸铵 、 碘 、 potassium carbonate 、 N-甲基吗啉氧化物 、 三苯基膦 、 偶氮二甲酸二乙酯 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 水 、 乙腈 为溶剂， 生成 [3"-Chloro-2-fluoro-5'-(8-phenyl-octylcarbamoyl)-[1,1';3',1"]terphenyl-2'-yloxy]-acetic acid
  参考文献：
  名称：

  方便合成功能化的三联苯

  摘要：

  描述了适合于快速合成差异官能化的三联苯的方便的合成方法。通过利用羟基乙氧基作为酸的前体，满足了结合苯氧基乙酸和羧酰胺官能团的正交性要求。已经开发出用于形成酸和酰胺的高效通用方法。

  DOI：

  10.1016/s0040-4039(03)00333-2

文献信息

• 2, 3, 5-substituted biphenyls useful in the treatment of insulin resistance and hyperglycemia
  申请人：——

  公开号：US20010018525A1

  公开（公告）日：2001-08-30

  This invention provides compounds of Formula I having the structure 1 wherein: B and D are each, independently, hydrogen, halogen, alkyl of 1-6 carbon atoms, cycloalkyl of 3-8 carbon atoms, aryl, heteroaryl, aralkyl of 6-12 carbon atoms, or heteroaralkyl of 6-12 carbon atoms except where B and D both are hydrogen; R 1 is hydrogen, alkyl of 1-6 carbon atoms, —SO 2 Ph(OH)(CO 2 H), —CH(R 2 )W; —CH 2 CH 2 Y, or —CH 2 CH 2 CH 2 Y; R 2 is hydrogen, alkyl of 1-6 carbon atoms, aralkyl of 6-12 carbon atoms, —CH 2 (1H-imidazol-4-yl), —CH 2 (3-1H-indolyl), —CH 2 CH 2 (1,3-dioxo-1,3-dihydro-isoindol-2-yl), —CH 2 CH 2 (1-oxo-1,3-dihydro-isoindol-2-yl), or —CH 2 (3-pyridyl); W is —CO 2 R 3 , —CONHOH, —CN, —CONHR 3 , aryl, heteroaryl, —CHO, —CH═NOR 3 , or —CH═NHNHR 3 ; Y is —W, —OCH 2 CO 2 R 3 , aryl, heteroaryl, —C(═NOH)NH 2 , —OR 3 , —O(C═O)NR 4 R 5 , —NR 3 (C═O)OR 3 , —NR 3 (C═O)NR 4 R 5 , or —NR 4 R 5 ; R 3 is hydrogen or alkyl of 1-6 carbon atoms; R 4 and R 5 are each, independently, hydrogen, or alkyl of 1-6 carbon atoms or R 4 and R 5 are, together, —(CH 2 ) n —, or —CH 2 CH 2 XCH 2 CH 2 —; X is O, S, SO, SO 2 , NR 3 , or CH 2 ; n is 2 to 5; C is alkyl of 1-18 carbon atoms, aryl, heteroaryl, aralkyl of 6-20 carbon atoms, heteroaralkyl of 6-20 carbon atoms, —CONR 6 R 7 , —NR 3 CONR 6 R 7 , —NR 3 COR 6 , —OR 6 , —O 2 CNR 6 R 7 , —NR 3 CO 2 R 6 , —O 2 CR 6 , —CH 2 OR 6 , —NR 6 R 7 , —CR 3 ═CR 3 R 8 , —CPh 3 , —CH 2 NR 6 R 7 , or 2 R 6 and R 7 are each, independently, hydrogen, alkyl of 1-18 carbon atoms, aryl, heteroaryl, aralkyl of 6-20 carbon atoms, heteroaralkyl of 6-20 carbon atoms, cycloalkyl of 3-10 carbon atoms, —(CH 2 CH 2 O) n CH 3 , —(CH 2 ) m A or R 6 and R 7 are, together, —(CH 2 ) p —, —(CH 2 ) 2 N(CH 3 )(CH 2 ) 4 —, —(CH 2 ) 2 N(R 8 )(CH 2 ) 2 —, or —(CH 2 ) 2 CH(R 8 )—(CH 2 ) 2 —; R 8 is hydrogen, alkyl of 1-18 carbon atoms, aryl, heteroaryl, aralkyl of 6-20 carbon atoms, heteroaralkyl of 6-20 carbon atoms, cycloalkyl of 3-10 carbon atoms, —(CH 2 CH 2 O) n CH 3 , —(CH 2 CH 2 CH 2 O) n CH 3 , or —(CH 2 ) m A; A is aryl, heteroaryl, aryloxy, heteroaryloxy, arylthio, heteroarylthio, arylsulfoxy, heteroarylsulfoxy, arylsulfonyl, heteroarylsulfonyl, —CHF 2 , —CH 2 F, —CF 3 , —(CH 2 CH 2 O) n CH 3 , —(CH 2 CH 2 CH 2 O) n CH 3 , —CO 2 R 3 , —O(C═O)NR 6 R 7 , aralkyloxy, or heteroaralkyloxy; m is 2 to 16 p is 2 to 12 or a pharmaceutically acceptable salt thereof, which are useful in treating metabolic disorders related to insulin resistance or hyperglycemia.

  该发明提供了具有结构1的化合物，其中： B和D分别独立地为氢、卤素、1-6个碳原子的烷基、3-8个碳原子的环烷基、芳基、杂芳基、6-12个碳原子的芳基烷基或6-12个碳原子的杂芳基烷基，但当B和D均为氢时除外。 R1为氢、1-6个碳原子的烷基、-SO2Ph(OH)(CO2H)、-CH(R2)W、-CH2CH2Y或-CH2CH2CH2Y。 R2为氢、1-6个碳原子的烷基、6-12个碳原子的芳基烷基、-CH2(1H-咪唑-4-基)、-CH2(3-1H-吲哚基)、-CH2CH2(1,3-二酮-1,3-二氢异吲哚-2-基)、-CH2CH2(1-酮-1,3-二氢异吲哚-2-基)或-CH2(3-吡啶基)。 W为-CO2R3、-CONHOH、-CN、-CONHR3、芳基、杂芳基、-CHO、-CH═NOR3或-CH═NHNHR3。 Y为-W、-OCH2CO2R3、芳基、杂芳基、-C(═NOH)NH2、-OR3、-O(C═O)NR4R5、-NR3(C═O)OR3、-NR3(C═O)NR4R5或-NR4R5。 R3为氢或1-6个碳原子的烷基。 R4和R5分别独立地为氢或1-6个碳原子的烷基，或者R4和R5在一起为-(CH2)n-或-CH2CH2XCH2CH2-，其中X为O、S、SO、SO2、NR3或CH2，n为2到5。 C为1-18个碳原子的烷基、芳基、杂芳基、6-20个碳原子的芳基烷基、6-20个碳原子的杂芳基烷基、-CONR6R7、-NR3CONR6R7、-NR3COR6、-OR6、-O2CNR6R7、-NR3CO2R6、-O2CR6、-CH2OR6、-NR6R7、-CR3═CR3R8、-CPh3、-CH2NR6R7或2R6和R7分别独立地为氢、1-18个碳原子的烷基、芳基、杂芳基、6-20个碳原子的芳基烷基、6-20个碳原子的杂芳基烷基、3-10个碳原子的环烷基、-(CH2CH2O)nCH3、-(CH2)mA，或者R6和R7在一起为-(CH2)p-、-(CH2)2N(CH3)(CH2)4-、-(CH2)2N(R8)(CH2)2-或-(CH2)2CH(R8)-(CH2)2-，其中R8为氢、1-18个碳原子的烷基、芳基、杂芳基、6-20个碳原子的芳基烷基、6-20个碳原子的杂芳基烷基、3-10个碳原子的环烷基、-(CH2CH2O)nCH3、-(CH2CH2CH2O)nCH3或-(CH2)mA；A为芳基、杂芳基、芳氧基、杂芳氧基、芳硫基、杂芳硫基、芳基亚磺酸基、杂芳基亚磺酸基、芳基磺酰基、杂芳基磺酰基、-CHF2、-CH2F、-CF3、-(CH2CH2O)nCH3、-(CH2CH2CH2O)nCH3、-CO2R3、-O(C═O)NR6R7、芳基烷氧基或杂芳基烷氧基；m为2到16；p为2到12。 或其药学上可接受的盐，适用于治疗与胰岛素抵抗或高血糖有关的代谢障碍。
• 2,3,5-substituted biphenyls useful in the treatment of insulin resistance and hyperglycemia
  申请人：Wyeth

  公开号：US20040214869A1

  公开（公告）日：2004-10-28

  This invention provides compounds of Formula I having the structure 1 wherein: B and D are each, independently, hydrogen, halogen, alkyl of 1-6 carbon atoms, cycloalkyl of 3-8 carbon atoms, aryl, heteroaryl, aralkyl of 6-12 carbon atoms, or heteroaralkyl of 6-12 carbon atoms except where B and D both are hydrogen; R 1 is hydrogen, alkyl of 1-6 carbon atoms, —SO 2 Ph(OH)(CO 2 H), —CH(R 2 )W, —CH 2 CH 2 Y, or —CH 2 CH 2 CH 2 Y; R 2 is hydrogen, alkyl of 1-6 carbon atoms, aralkyl of 6-12 carbon atoms, —CH 2 (1H-imidazol-4-yl), —CH 2 (3-1H-indolyl), —CH 2 CH 2 (1,3-dioxo-1,3-dihydro-isoindol-2-yl), —CH 2 CH 2 (1-oxo-1,3-dihydro-isoindol-2-yl), or —CH 2 (3-pyridyl); W is —CO 2 R 3 , —CONHOH, —CN, —CONHR 3 , aryl, heteroaryl, —CHO, —CH═NOR 3 , or —CH═NHNHR 3 ; Y is —W, —OCH 2 CO 2 R 3 , aryl, heteroaryl, —C(═NOH)NH 2 , —OR 3 , —O(C═O)NR 4 R 5 , —NR 3 (C═O)OR 3 , —NR 3 (C═O)NR 4 R 5 , or —NR 4 R 5 ; R 3 is hydrogen or alkyl of 1-6 carbon atoms; R 4 and R 5 are each, independently, hydrogen, or alkyl of 1-6 carbon atoms or R 4 and R 5 are, together, —(CH 2 ) n —, or —CH 2 CH 2 XCH 2 CH 2 —; X is O, S, SO, SO 2 , NR 3 , or CH 2 ; n is 2 to 5; C is alkyl of 1-18 carbon atoms, aryl, heteroaryl, aralkyl of 6-20 carbon atoms, heteroaralkyl of 6-20 carbon atoms, —CONR 6 R 7 , —NR 3 CONR 6 R 7 , —NR 3 COR 6 , —OR 6 , —O 2 CNR 6 R 7 , —NR 3 CO 2 R 6 , —O 2 CR 6 , —CH 2 OR 6 , —NR 6 R 7 , —CR 3 ═CR 3 R 8 , —CPh 3 , —CH 2 NR 5 R 6 , or 2 R 6 and R 7 are each, independently, hydrogen, alkyl of 1-18 carbon atoms, aryl, heteroaryl, aralkyl of 6-20 carbon atoms, heteroaralkyl of 6-20 carbon atoms, cycloalkyl of 3-10 carbon atoms, —(CH 2 CH 2 O) n CH 3 , —(CH 2 ) m A or R 6 and R 7 are, together, —(CH 2 ) p —, —(CH 2 ) 2 N(CH 3 )(CH 2 ) 4 —, —(CH 2 ) 2 N(R 8 )(CH 2 ) 2 —, or —(CH 2 ) 2 CH(R 8 )—(CH 2 ) 2 —; R 8 is hydrogen, alkyl of 1-18 carbon atoms, aryl, heteroaryl, aralkyl of 6-20 carbon atoms, heteroaralkyl of 6-20 carbon atoms, cycloalkyl of 3-10 carbon atoms, —(CH 2 CH 2 O) n CH 3 , —(CH 2 CH 2 CH 2 O) n CH 3 , or —(CH 2 ) m A; A is aryl, heteroaryl, aryloxy, heteroaryloxy, arylthio, heteroarylthio, arylsulfoxy, heteroarylsulfoxy, arylsulfonyl, heteroarylsulfonyl, —CHF 2 , —CH 2 F, —CF 3 , —(CH 2 CH 2 O) n CH 3 , —(CH 2 CH 2 CH 2 O) n CH 3 , —CO 2 R 3 , —O(C═O)NR 6 R 7 , aralkyloxy, or heteroaralkyloxy; m is 2 to 16 p is 2 to 12 or a pharmaceutically acceptable salt thereof, which are useful in treating metabolic disorders related to insulin resistance or hyperglycemia.

  这项发明提供了具有结构1的化合物，其中：B和D各自独立地为氢、卤素、1-6个碳原子的烷基、3-8个碳原子的环烷基、芳基、杂芳基、6-12个碳原子的芳基烷基或6-12个碳原子的杂芳基烷基，但当B和D都为氢时除外；R1为氢、1-6个碳原子的烷基、-SO2Ph(OH)(CO2H)、-CH(R2)W、-CH2CH2Y或-CH2CH2CH2Y；R2为氢、1-6个碳原子的烷基、6-12个碳原子的芳基烷基、-CH2(1H-咪唑-4-基)、-CH2(3-1H-吲哚基)、-CH2CH2(1,3-二酮-1,3-二氢-异吲哚-2-基)、-CH2CH2(1-酮-1,3-二氢-异吲哚-2-基)或-CH2(3-吡啶基)；W为-CO2R3、-CONHOH、-CN、-CONHR3、芳基、杂芳基、-CHO、-CH═NOR3或-CH═NHNHR3；Y为-W、-OCH2CO2R3、芳基、杂芳基、-C(═NOH)NH2、-OR3、-O(C═O)NR4R5、-NR3(C═O)OR3、-NR3(C═O)NR4R5或-NR4R5；R3为氢或1-6个碳原子的烷基；R4和R5各自独立地为氢或1-6个碳原子的烷基，或R4和R5在一起为-(CH2)n-或-CH2CH2XCH2CH2-；X为O、S、SO、SO2、NR3或CH2；n为2至5；C为1-18个碳原子的烷基、芳基、杂芳基、6-20个碳原子的芳基烷基、6-20个碳原子的杂芳基烷基、-CONR6R7、-NR3CONR6R7、-NR3COR6、-OR6、-O2CNR6R7、-NR3CO2R6、-O2CR6、-CH2OR6、-NR6R7、-CR3═CR3R8、-CPh3、-CH2NR5R6或2R6和R7各自独立地为氢、1-18个碳原子的烷基、芳基、杂芳基、6-20个碳原子的芳基烷基、6-20个碳原子的杂芳基烷基、3-10个碳原子的环烷基、-(CH2CH2O)nCH3、-(CH2)mA或R6和R7在一起为-(CH2)p-、-(CH2)2N(CH3)(CH2)4-、-(CH2)2N(R8)(CH2)2-或-(CH2)2CH(R8)-(CH2)2-；R8为氢、1-18个碳原子的烷基、芳基、杂芳基、6-20个碳原子的芳基烷基、6-20个碳原子的杂芳基烷基、3-10个碳原子的环烷基、-(CH2CH2O)nCH3、-(CH2CH2CH2O)nCH3或-(CH2)mA；A为芳基、杂芳基、芳氧基、杂芳氧基、芳硫基、杂芳硫基、芳基磺酸氧基、杂芳基磺酸氧基、芳基磺酰基、杂芳基磺酰基、-CHF2、-CH2F、-CF3、-(CH2CH2O)nCH3、-(CH2CH2CH2O)nCH3、-CO2R3、-O(C═O)NR6R7、芳基烷氧基或杂芳基烷氧基；m为2至16；p为2至12；或其药学上可接受的盐，其可用于治疗与胰岛素抵抗或高血糖相关的代谢紊乱。
• 2,3,5-Substituted biphenyls useful in the treatment of insulin resistance and hyperglycemia
  申请人：Wyeth

  公开号：US20030083341A1

  公开（公告）日：2003-05-01

  This invention provides compounds of Formula I having the structure 1 wherein: B and D are each, independently, hydrogen, halogen, alkyl of 1-6 carbon atoms, cycloalkyl of 3-8 carbon atoms, aryl, heteroaryl, aralkyl of 6-12 carbon atoms, or heteroaralkyl of 6-12 carbon atoms except where B and D both are hydrogen; R 1 is hydrogen, alkyl of 1-6 carbon atoms, —SO 2 Ph(OH)(CO 2 H), —CH(R 2 )W, —CH 2 CH 2 Y, or —CH 2 CH 2 CH 2 Y; R 2 is hydrogen, alkyl of 1-6 carbon atoms, aralkyl of 6-12 carbon atoms, —CH 2 (1H-imidazol-4-yl), —CH 2 (3-1H-indolyl), —CH 2 CH 2 (1,3-dioxo-1,3-dihydro-isoindol-2-yl), —CH 2 CH 2 (1-oxo-1,3-dihydro-isoindol-2-yl), or —CH 2 (3-pyridyl); W is —CO 2 R 3 , —CONHOH, —CN, —CONHR 3 , aryl, heteroaryl, —CHO, —CH═NOR 3 , or —CH═NHNHR 3 ; Y is —W, —OCH 2 CO 2 R 3 , aryl, heteroaryl, —C(═NOH)NH 2 , —OR 3 , —O(C═O)NR 4 R 5 , —NR 3 (C═O)OR 3 , —NR 3 (C═O)NR 4 R 5 , or —NR 4 R 5 ; R 3 is hydrogen or alkyl of 1-6 carbon atoms; R 4 and R 5 are each, independently, hydrogen, or alkyl of 1-6 carbon atoms or R 4 and R 5 are, together, —(CH 2 ) n —, or —CH 2 CH 2 XCH 2 CH 2 —; X is O, S, SO, SO 2 , NR 3 , or CH 2 ; n is 2 to 5; C is alkyl of 1-18 carbon atoms, aryl, heteroaryl, aralkyl of 6-20 carbon atoms, heteroaralkyl of 6-20 carbon atoms, —CONR 6 R 7 , —NR 3 CONR 6 R 7 , —NR 3 COR 6 , —OR 6 , —O 2 CNR 6 R 7 , —NR 3 CO 2 R 6 , —O 2 CR 6 , —CH 2 OR 6 , —NR 6 R 7 , —CR 3 ═CR 3 R 8 , —CPh 3 , —CH 2 NR 6 R 7 , or 2 R 6 and R 7 are each, independently, hydrogen, alkyl of 1-18 carbon atoms, aryl, heteroaryl, aralkyl of 6-20 carbon atoms, heteroaralkyl of 6-20 carbon atoms, cycloalkyl of 3-10 carbon atoms, —(CH 2 CH 2 O) n CH 3 , —(CH 2 ) m A or R 6 and R 7 are, together, —(CH 2 ) p —, —(CH 2 ) 2 N(CH 3 )(CH 2 ) 4 —, —(CH 2 ) 2 N(R 8 )(CH 2 ) 2 —, or —(CH 2 ) 2 CH(R 8 )—(CH 2 ) 2 —; R 8 is hydrogen, alkyl of 1-18 carbon atoms, aryl, heteroaryl, aralkyl of 6-20 carbon atoms, heteroaralkyl of 6-20 carbon atoms, cycloalkyl of 3-10 carbon atoms, —(CH 2 CH 2 O) n CH 3 , —(CH 2 CH 2 CH 2 O) n CH 3 , or —(CH 2 ) m A; A is aryl, heteroaryl, aryloxy, heteroaryloxy, arylthio, heteroarylthio, arylsulfoxy, heteroarylsulfoxy, arylsulfonyl, heteroarylsulfonyl, —CHF 2 , —CH 2 F, —CF 3 , —(CH 2 CH 2 O) n CH 3 , —(CH 2 CH 2 CH 2 O) n CH 3 , —CO 2 R 3 , —O(C═O)NR 6 R 7 , aralkyloxy, or heteroaralkyloxy; m is 2 to 16 p is 2 to 12 or a pharmaceutically acceptable salt thereof, which are useful in treating metabolic disorders related to insulin resistance or hyperglycemia.

  该发明提供了公式I的化合物，其结构为1其中：B和D各自独立地为氢、卤素、1-6碳原子的烷基、3-8碳原子的环烷基、芳基、杂芳基、6-12碳原子的芳基烷基或除B和D均为氢外的6-12碳原子的杂芳基烷基；R1为氢、1-6碳原子的烷基、—SO2Ph(OH)(CO2H)、—CH(R2)W、—CH2CH2Y或—CH2CH2CH2Y；R2为氢、1-6碳原子的烷基、6-12碳原子的芳基烷基、—CH2(1H-咪唑-4-基)、—CH2(3-1H-吲哚基)、—CH2CH2(1,3-二酮-1,3-二氢-异吲哚-2-基)、—CH2CH2(1-氧代-1,3-二氢-异吲哚-2-基)或—CH2(3-吡啶基)；W为—CO2R3、—CONHOH、—CN、—CONHR3、芳基、杂芳基、—CHO、—CH═NOR3或—CH═NHNHR3；Y为—W、—OCH2CO2R3、芳基、杂芳基、—C(═NOH)NH2、—OR3、—O(C═O)NR4R5、—NR3(C═O)OR3、—NR3(C═O)NR4R5或—NR4R5；R3为氢或1-6碳原子的烷基；R4和R5各自独立地为氢、1-6碳原子的烷基或R4和R5在一起为—(CH2)n—或—CH2CH2XCH2CH2—；X为O、S、SO、SO2、NR3或CH2；n为2至5；C为1-18碳原子的烷基、芳基、杂芳基、6-20碳原子的芳基烷基、6-20碳原子的杂芳基烷基、—CONR6R7、—NR3CONR6R7、—NR3COR6、—OR6、—O2CNR6R7、—NR3CO2R6、—O2CR6、—CH2OR6、—NR6R7、—CR3═CR3R8、—CPh3、—CH2NR6R7或2R6和R7各自独立地为氢、1-18碳原子的烷基、芳基、杂芳基、6-20碳原子的芳基烷基、6-20碳原子的杂芳基烷基、3-10碳原子的环烷基、—(CH2CH2O)nCH3、—(CH2)mA或R6和R7在一起为—(CH2)p—、—(CH2)2N(CH3)(CH2)4—、—(CH2)2N(R8)(CH2)2—或—(CH2)2CH(R8)—(CH2)2—；R8为氢、1-18碳原子的烷基、芳基、杂芳基、6-20碳原子的芳基烷基、6-20碳原子的杂芳基烷基、3-10碳原子的环烷基、—(CH2CH2O)nCH3、—(CH2CH2CH2O)nCH3或—(CH2)mA；A为芳基、杂芳基、芳氧基、杂芳氧基、芳硫基、杂芳硫基、芳基磺酸氧基、杂芳基磺酸氧基、芳基磺酰基、杂芳基磺酰基、—CHF2、—CH2F、—CF3、—(CH2CH2O)nCH3、—(CH2CH2CH2O)nCH3、—CO2R3、—O(C═O)NR6R7、芳基烷氧基或杂芳基烷氧基；m为2至16；p为2至12；或其药学上可接受的盐，用于治疗与胰岛素抵抗或高血糖相关的代谢紊乱。
• US6214877B1
  申请人：——

  公开号：US6214877B1

  公开（公告）日：2001-04-10
• Convenient synthesis of functionalized terphenyls
  作者：A.A. Greenfield、J.A. Butera、C.E. Caufield

  DOI：10.1016/s0040-4039(03)00333-2

  日期：2003.3

  A convenient synthetic methodology amenable for rapid synthesis of differentially functionalized terphenyls is described. Orthogonality requirements for the incorporation of phenoxy acetic acid and carboxamide function have been satisfied by utilization of hydroxyethoxy group as a precursor of the acid. Highly efficient and universal procedures have been developed for acid and amide formation.

  描述了适合于快速合成差异官能化的三联苯的方便的合成方法。通过利用羟基乙氧基作为酸的前体，满足了结合苯氧基乙酸和羧酰胺官能团的正交性要求。已经开发出用于形成酸和酰胺的高效通用方法。